News and Media

Remarkable uptake in Quantum Genomics IPO:1 €11.2 million raised

17 February 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC) announces the great success of its Initial Public Offering on the Euronext Alternext market in Paris.

> Strong demand: €33.2 million, or global offering 3.4 times oversubscribed
> Share price set at top end of price range at […]

Quantum Genomics is launching a public equity offering on Alternext Paris, above all to fund the phase IIa clinical trials of its antihypertensive drug candidate QGC001

27 January 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC) announces the launch of a public equity offering of approximately 9.1 M€ on the Alternext market, part of Euronext Paris.

     > Capital increase of approximately 9.1 M€,
     > Purchase agreement with shareholders for […]

2015/01/12 – Quantum Genomics at J.P. Morgan 34th annual healthcare conference

12 January 2015
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces its presence at J.P. Morgan 34th annual healthcare conference taking place from January 12 to January 15, 2015, in San Francisco […]

Catherine Llorens-Cortes receives the 2014 Galien France pharmaceutical research award for her work on the key role of angiotensin III at brain level in the control of blood pressure

11 December 2014
|

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, is pleased to announce that Dr Catherine Llorens-Cortes has been given the Galien France award (research category), presented at the 45th edition […]